NASDAQ, SRDX #Financial Report Scheduled #Upcoming Clinical Trial Presentation Surmodics to Report First Quarter of Fiscal 2023 Financial Results on February 6 January 26, 2023 08:30 EST EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that first quarter of fiscal year 2023 financial results will be released after the market closes on Monday, February 6. Management will host a live No Comments
NASDAQ, NAUT #Financial Report Scheduled #Upcoming Clinical Trial Presentation Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023 January 26, 2023 08:00 EST SEATTLE, Jan. 26, 2023 (GLOBE NEWSWIRE) — Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the fourth quarter and full year of 2022 before market open on Thursday, February 23, 2023. The company’s management No Comments
AGEN, NASDAQ #Cancer #Investor Conference #Upcoming Clinical Trial Presentation Agenus to Participate in February Investor Conferences January 26, 2023 07:30 EST LEXINGTON, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) — Agenus (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, today announced that Dr. Garo Armen, Chairman and CEO, and Dr. Steven O’Day, Chief Medical Officer, will participate in the following upcoming investor conferences: No Comments
MDNA, NASDAQ #Financial Report Scheduled #Upcoming Clinical Trial Presentation Medicenna to Announce Third Quarter Fiscal 2023 Financial Results and Operational Highlights on Tuesday, February 7, 2023 January 26, 2023 07:00 EST TORONTO and HOUSTON, Jan. 26, 2023 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on February 7, 2023 at 8:30 AM ET to report its third No Comments
IQV, NYSE #Financial Report Scheduled #Upcoming Clinical Trial Presentation IQVIA to Announce Fourth-Quarter and Full-Year 2022 Results on February 10, 2023 January 25, 2023 16:15 EST RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV) will announce its fourth-quarter and full-year 2022 financial results before the market opens on Friday, February 10, 2023. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. No Comments
INNV, NASDAQ #Financial Report Scheduled #Upcoming Clinical Trial Presentation InnovAge to Announce Fiscal Second Quarter 2023 Financial Results and Host Conference Call Tuesday, February 7, 2023 January 24, 2023 16:05 EST DENVER, Jan. 24, 2023 (GLOBE NEWSWIRE) — InnovAge Holding Corp. (“InnovAge”) (Nasdaq: INNV) will release its 2023 fiscal second quarter financial results on Tuesday, February 7, 2023, after market close. In conjunction, the company will host a conference call to review the results at 5 p.m. E.T. Conference Call No Comments
ATRC, NASDAQ #Financial Report Scheduled #Upcoming Clinical Trial Presentation AtriCure to Announce Fourth Quarter and Full Year 2022 Financial Results and Participate in 2023 BTIG Medical Technology Conference January 24, 2023 08:00 EST MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2022 financial results on Tuesday, February 21, 2023. AtriCure will No Comments
CFMS, NASDAQ #Financial Report Scheduled #Upcoming Clinical Trial Presentation Conformis, Inc. to Announce Financial Results for Its Fourth Quarter and Full-Year 2022 January 23, 2023 16:30 EST BILLERICA, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) — Conformis, Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today it will release its financial results for the fourth quarter and full-year ended December 31, 2022, after the market closes on Wednesday, No Comments
NASDAQ, UNCY #kidney #Trending News #Upcoming Clinical Trial Presentation Unicycive Announces Acceptance of Three Abstracts for Presentation at the National Kidney Foundation’s Spring Clinical Meetings January 23, 2023 07:00 EST LOS ALTOS, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that three abstracts have been accepted for presentation at the National Kidney Foundation’s (NFK) upcoming Spring Clinical Meetings taking place in Austin, Texas No Comments
LVTX, NASDAQ #Cancer #Upcoming Clinical Trial Presentation LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium January 23, 2023 07:00 EST UTRECHT, The Netherlands and PHILADELPHIA, Jan. 23, 2023 (GLOBE NEWSWIRE) — LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced that clinical data from a Phase 1/2a study in No Comments
Scilex Holding Company Announces that its Majority Stockholder, Sorrento Therapeutics, Inc., has Issued an “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock 01/29/2023
STEER Announces a Proposed Transaction for an $18 Million Direct Investment Involving its Digital Restaurant Supply Business (B2B Marketplace) 01/23/2023
Ra Medical Systems Announces the Presentation of Clinical Data at the European Heart Rhythm Association Congress 01/23/2023
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Silvergate Capital Corporation Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – SI 01/23/2023